Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI – Get Free Report)’s share price crossed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $0.64 and traded as high as $0.65. Brainstorm Cell Therapeutics shares last traded at $0.6233, with a volume of 12,095 shares changing hands.
Brainstorm Cell Therapeutics Price Performance
The business has a fifty day moving average of $0.58 and a 200 day moving average of $0.64. The stock has a market cap of $6.88 million, a PE ratio of -0.19 and a beta of 0.67.
Brainstorm Cell Therapeutics Company Profile
BrainStorm Cell Therapeutics Inc (NASDAQ: BCLI) is a clinical‐stage biotechnology company focused on developing autologous cell therapies for the treatment of neurodegenerative diseases. The company’s proprietary platform leverages mesenchymal stem cells (MSCs) that are engineered to secrete neurotrophic and growth factors designed to support neuronal survival and function.
The company’s lead product candidate, NurOwn, is an autologous MSC therapy currently in advanced clinical development for amyotrophic lateral sclerosis (ALS).
See Also
- Five stocks we like better than Brainstorm Cell Therapeutics
- REVEALED: Something Big Happening Behind White House Doors
- ALERT: Drop these 5 stocks before the market opens tomorrow!
- Elon Musk: This Could Turn $100 into $100,000
- Read this or regret it forever
- The Next Commodity Crunch (bigger than oil?)
Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
